2025
Current Advances in Anticancer Properties of Heptamethine Carbocyanine DZ‐1 Conjugated to Artesunate: Generation of Reactive Oxygen Species
Narayanasamy B, Helmueller S, Zhang Y, Lee Y. Current Advances in Anticancer Properties of Heptamethine Carbocyanine DZ‐1 Conjugated to Artesunate: Generation of Reactive Oxygen Species. Journal Of Cellular Biochemistry 2025, 126: e70062. PMID: 40891511, DOI: 10.1002/jcb.70062.Peer-Reviewed Original ResearchConceptsCancer cellsMechanism of actionGeneration of reactive oxygen speciesReactive oxygen speciesN-acetyl cysteine treatmentKilling of cancer cellsCell linesDUTP nick end labeling assayDose-dependent cytotoxic activityNick end labeling assayTransferase dUTP nick end labeling assayBax-deficient HCT116 cellsTerminal deoxynucleotidyl transferase dUTP nick end labeling assayDeoxynucleotidyl transferase dUTP nick end labeling assayCell survival assayOVCAR-3 cell lineMitochondrial outer membrane potentialTreated cancer cellsInvolvement of apoptosisSuppression of ROS generationWild-type cellsOuter membrane potentialCancer cell linesAnticancer propertiesJC-1 assay
1999
The proteasome inhibitor PS-341 in cancer therapy.
Teicher B, Ara G, Herbst R, Palombella V, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clinical Cancer Research 1999, 5: 2638-45. PMID: 10499643.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBoronic AcidsBortezomibBreast NeoplasmsCisplatinCyclophosphamideDipeptidesDrug SynergismHumansMammary Neoplasms, ExperimentalMiceMice, Inbred BALB CProtease InhibitorsPyrazinesRadiation-Sensitizing AgentsTumor Cells, CulturedUbiquitinsConceptsProteasome inhibitor PS-341PS-341EMT-6/CDDP tumorAdditive tumor growth delayCancer therapyEMT-6/CTXTumor cell survival assayTumor growth delay assayLewis lung carcinomaColony-forming unit-granulocyte macrophageTumor growth delayGrowth delay assayHuman breast carcinoma cellsMCF-7 human breast carcinoma cellsUnit-granulocyte macrophageTumor cell killingCell survival assayBreast carcinoma cellsMetastatic diseaseInteresting new targetLung carcinomaRadiation therapyVivo resistanceGrowth delayParent tumor
1998
Acute in vivo resistance in high-dose therapy.
Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E. Acute in vivo resistance in high-dose therapy. Clinical Cancer Research 1998, 4: 483-91. PMID: 9516940.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCyclophosphamideDisease Models, AnimalDose-Response Relationship, DrugDrug Resistance, MultipleDrug Resistance, NeoplasmFemaleMammary Neoplasms, ExperimentalMelphalanMiceMice, Inbred BALB CNeoplasm TransplantationPaclitaxelThiotepaConceptsTumor growth delayAdditive tumor growth delayHigh-dose cyclophosphamideHigh-dose melphalanGrowth delaySecond highest doseHigh doseSequential high-dose chemotherapyTumor cell survival assayEMT-6 mammary carcinomaTumor growth delay studiesBone marrow colony-forming unitsHigh-dose therapyMarrow colony-forming unitsHigh-dose chemotherapyBone marrow CFU-GMHigh-dose treatmentGrowth delay studiesTumor-bearing miceMarrow CFU-GMSolid tumor modelsCell survival assayCombination regimensMammary carcinomaCyclophosphamide
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply